Biaoxue R, Shuanying Y, Wei L et al., 2012. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Curr Med Res Opin, 28, 1699-1708.
Borghaei H, Paz-Ares L, Horn L et al., 2015. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 373, 1627-1639.
Brahmer J, Reckamp KL, Baas P et al., 2015. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 373,123-135.
Cufer T, Vrdoljak E, Gaafar R, Erensoy I, Pemberton K et al., 2006. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer. Anticancer Drugs, 17, 401-409.
Fehrenbacher L, Spira A, Ballinger M, et al., 2016. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387, 1837-1846.
Gettinger SN, Horn L, Gandhi L, et al., 2015. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients with Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 33, 2004-2012
Herbst RS, Baas P, Kim DW et al., 2016. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387, 1540-1550.
Hida T, Kaji R, Satouchi M, et al., 2018. Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. Clin Lung Cancer, 19(4), e405-e415.
Kiefer C, Sturtz S, Bender R. 2015. Indirect Comparisons and Network Meta-Analyses. Dtsch Arztebl Int, 112, 803-808.
Kim ES, Hirsh V, Mok T et al., 2008. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 372, 1809-1818.
Lee DH, Park K, Kim JH et al., 2010. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res, 16: 1307-1314.
Lim E, Harris G, Patel A, Adachi I, Edmonds L et al., 2009. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol, 4, 1380-1388.
Maruyama R, Nishiwaki Y, Tamura T et al., Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol, 26, 4244-4252.
Mok TS, Wu YL, Thongprasert S et al., 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-957.
Morere JF, Brechot JM, Westeel V et al., 2010. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer, 70, 301-307.
Qi WX, Shen Z, Lin F et al., 2012. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 5177-5182.
Rangachari D, Brahmer JR. 2013. Targeting the immune system in the treatment of non-small-cell lung cancer. Curr Treat Options Oncol, 14, 580-594.
Rittmeyer A, Barlesi F, Waterkamp D et al., 2017. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 389, 255-265.
Shimanovsky A, Jethava A, Dasanu CA. 2013. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther, 13,1413-1427.
Sormani MP. 2017. Indirect comparisons of treatment effects: Network meta-analyses. Mult Scler, 23, 510-512.
Sun JM, Lee KH, Kim SW et al., 2012. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer, 118, 6234-6242.
Sun Y, Wu YL, Li LY et al., 2011. Efficacy and safety of gefitinib or docetaxel in Chinese pa tients with locally advanced or metastatic non -small cell lung cancer (NSCLC) who had failed previous platinum -based first-line chemotherapy. Chin J Onco, 5, 377-380.
Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA. 2014. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer, 85,101-109.
Vokes EE, Ready N, Felip E et al., 2018. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol, 29, 959-965.